The number of studies that have found a link between a disease and a specific gut microbiome composition seems to be ever increasing.
Until recently, almost all these studies have looked at single diseases in isolation. But most people tend to have more than one health complaint at a time – “comorbidities”, in medical parlance.
For our latest study, published in Nature Communications, we looked at the gut microbe composition across a range of diseases. What we found surprised us. The kind of microbes (such as Enterobacteriaceae) that increased in one disease, increased in nearly all 38 diseases studied. Also, some microbes that might be considered to be “healthy gut microbes”, were reduced in all 38 diseases studied.
4D pharma plc (LON:DDDD) is a pharmaceutical company focused on developing therapeutics from the human gut microbiome. 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism (such as a bacteria) that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies novel bacteria that have a precise and evolved therapeutic effect.
